
Few years ago the Food and Drug Administration (FDA) approved Betaseron (interferon beta-1b) as the first and only agent for the treatment of multiple sclerosis (MS). This approval was a beacon of hope for the more than 300,000 Americans who are afflicted with this central nervous system disease which usually first appears in young adulthood and which disables by causing problems with vision, strength, coordination, speech, bladder control, sensation, or other faculties governed by the eyes, brain, or spinal cord.